Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy via glycolysis and oxidative phosphorylation.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion: 1-1.5 g amino acids/kg/day (equivalent to 28-43 mL/kg/day of Aminosyn II 3.5% in D5W). Rate: infuse via central line at ≤100 mL/hour; peripheral line at ≤125 mL/hour. Adjust based on nitrogen balance and metabolic response.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Not applicable as a mixture; individual components have varying half-lives. Dextrose: rapid distribution, half-life <1 hour. Amino acids: half-life of infused amino acids is short (minutes) due to metabolism.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Aminosyn II 3.5% in Dextrose 5% contains amino acids and dextrose. Amino acids are metabolized; negligible renal excretion of intact amino acids. Dextrose is metabolized. No biliary/fecal elimination of intact drug.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution